Recent Company News

• 09:45 AM ET Jul 29, 2026
  

  Transcript Intelligence: Recordati Q2 Earnings Guidance

• 09:45 AM ET Jul 29, 2026
  

  Transcript Intelligence: Recordati Q2 Earnings Q&A

• 09:45 AM ET Jul 29, 2026
  

  Transcript Intelligence: Recordati Q2 Earnings Themes

• 12:00 PM ET Jul 28, 2026
  

  Recordati reports H1 adj net income €349.9M vs FactSet €340.1M; confirms its FY26 and FY27 financial targets (€51.30, 0.00)

• 07:08 PM ET Jul 21, 2026
  

  President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social

• 11:41 AM ET Jul 20, 2026
  

  StreetAccount M&A Summary: Week of 13-Jul

• 01:20 AM ET Jul 16, 2026
  

  Recordati's board deems the CVC's offer consideration of €51.29 per share to be fair (€51.30, 0.00)

• 03:30 PM ET Jul 08, 2026
  

  CONSOB approves Respighi BidCo's offer document in connection with acquisition of Recordati (€51.60, 0.00)

• 03:10 AM ET Jun 25, 2026
  

  Recordati enters into license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and commercialization rights to Zilganersen (€51.55, 0.00)

• 02:59 AM ET Jun 22, 2026
  

  StreetAccount Summary - European pre-market trading update